Journal
AUTOIMMUNITY REVIEWS
Volume 12, Issue 9, Pages 885-893Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.autrev.2013.03.011
Keywords
Myasthenia gravis; B cells; Anti-acetylcholine receptor antibodies; Germinal centers; BAFF; Anti-B-cell therapies
Categories
Funding
- European Union FIGHT-MG [242210]
- Parker Webber Endowed Chair in Neurology (Detroit Medical Center/Wayne State University)
- Mary Parker Neuroscience Fund (Detroit Medical Center)
- Muscular Dystrophy Association
Ask authors/readers for more resources
Myasthenia gravis (MG) is an autoimmune disease mediated by antibodies directed to molecules of the endplate of the neuromuscular junction. B cells play a major role in MG disease since they produce the pathogenic antibodies and therapies targeting B cells are effective. The aim of this article was to review the role of B cells in myasthenia gravis. We will first describe what we know about B cells in this disease and examine the involvement of the B cells in the thymus of MG patients. We will detail the role of factors associated with B-cell function such as BAFF. Finally, we will discuss the effects of therapy targeting B cells. (C) 2013 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available